Papers about tirzepatide

Every paper here, unless its row says otherwiseIndexed under tirzepatide in PubMed's chemical list; returned by a PubMed search for tirzepatide

• Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.

  The Journal of clinical endocrinology and metabolism2022PMID 34608929

• A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.

  Diabetes, obesity & metabolism2022PMID 34647404

• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

  JAMA2022PMID 35133415

• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.

  Nature medicine2022PMID 35210595

• Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

  The lancet. Diabetes & endocrinology2022PMID 35468321

• Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.

  The lancet. Diabetes & endocrinology2022PMID 35468322Indexed under tirzepatide in PubMed's chemical list

• Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

  The lancet. Diabetes & endocrinology2022PMID 35468325

• Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

  Diabetologia2022PMID 35579691Also tests tirzepatide

• Tirzepatide Once Weekly for the Treatment of Obesity.

  The New England journal of medicine2022PMID 35658024

• Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.

  The lancet. Diabetes & endocrinology2022PMID 35914542

• Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.

  The lancet. Diabetes & endocrinology2022PMID 35914543

• Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

  The lancet. Diabetes & endocrinology2022PMID 36152639

• Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.

  Diabetes & metabolic syndrome2022PMID 36274410

• Tirzepatide: A Systematic Update.

  International journal of molecular sciences2022PMID 36498958Returned by a PubMed search for tirzepatide

• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.

  The Journal of clinical endocrinology and metabolism2021PMID 33236115

• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

  The New England journal of medicine2021PMID 34170647Indexed under tirzepatide in PubMed's chemical list

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

  Lancet (London, England)2021PMID 34186022

• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

  Lancet (London, England)2021PMID 34370970Indexed under tirzepatide in PubMed's chemical list

• Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

  Diabetes, obesity & metabolism2020PMID 31984598

• Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

  Diabetes care2020PMID 32291277

• The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

  Diabetes, obesity & metabolism2020PMID 33462955